Search
Propylene glycol
go.drugbank.com/drugs/DB01839ApprovedInvestigationalA clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.
Mixtures: Secret Key Tattoo Cover Cushion Spf50 Plus (21 Light Beige), Secret Key Tattoo Cover Cushion Spf50 Plus (23 Natural Beige)ZYC300
go.drugbank.com/drugs/DB04986InvestigationalZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.
Dostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigational[L33340] This indication was granted full FDA approval on February 10, 2023.[L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month. … In April 2021, dostarlimab was granted accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair
Sulfamethoxazole
go.drugbank.com/drugs/DB01015ApprovedInvestigationalSulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic ac...
Mixtures: K.B. FAMATE, K.B. FAMATE SUSPENSIONDolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigational[A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013.
Iberdomide
go.drugbank.com/drugs/DB12101Investigational[L64055,L64056] It is the first cereblon E3 ligase modulator (CELMoD) approved for multiple myeloma.[L64057] … [L64055] The FDA granted iberdomide accelerated approval on August 13, 2026, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received
Categories: Cereblon E3 ligase modulatorRidogrel
go.drugbank.com/drugs/DB01207ExperimentalHowever, there currently are no clinical indications for preferential use of ridogrel over aspirin.
Growth hormone-releasing peptide 1
go.drugbank.com/drugs/DB19259InvestigationalGrowth hormone-releasing peptide 1 is under investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics
Goserelin
go.drugbank.com/drugs/DB00014ApprovedInvestigationalGoserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the...
Catridecacog
go.drugbank.com/drugs/DB09310ApprovedCoagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … Coagulation Factor XIII A-Subunit (Recombinant), also known as catridecacog, is a recombinant form of the Factor XIII-A2 homodimer composed of two factor XIII (FXIII) A-subunits [FDA Label].